Antiviral gap analysis for partnering and/or progression to IND

Challenge: A prominent researcher at an academic research institution had developed a class of small molecule compounds with in vitro antiviral activity against a family of RNA viruses. The...
Learn More

US and European partner outreach for Asian pharma companies

Challenge: A South Korean consulting firm required support in exploratory partner outreach in the US and Europe. Alacrita was commissioned to use its expertise in pharma licensing and deal-making in...
Learn More

Valuation of a lead pipeline agent

Challenge: A privately-funded preclinical stage biotech company asked Alacrita for a valuation of their lead pipeline agent for use in discussions with VC investors regarding their next financing...
Learn More

Technical & Commercial Due Diligence of a Portfolio of Biotech Companies

Challenge: A PE fund was looking at the potential purchase of a package of minority holdings in a portfolio of biotech companies on the secondary market. The fund approached Alacrita to conduct a due...
Learn More

Technical due diligence for a high-profile M&A transaction

Challenge: For a competitive M&A transaction, Alacrita was commissioned to conduct a technical due diligence of a major public drug delivery contract development and manufacturing organization. This...
Learn More

Due diligence on a product for ARDS in COVID-19 patients

Challenge: A family office was considering an investment in a US-based biotech company developing a product aimed at improving impaired oxygen transport in COVID-19 patients. Using its expert...
Learn More

Pre-DD on portfolio of repurposed drug products targeting CNS indications

Challenge: A VC firm was interested in a US-based drug repurposing company and asked Alacrita to perform a high level technical due diligence exercise to help the firm make an informed decision about...
Learn More

Valuation of a re-purposed combination drug for Alzheimer's disease

Challenge: A clinical stage biotech company developing treatments for Alzheimer's disease was looking for a valuation of its Phase II-ready therapeutic drug. The drug was a re-purposed combination of...
Learn More

Due Diligence on a bioinformatics platform to repurpose clinical-stage drugs

Challenge: Our client, a VC firm based in Dubai, was planning to invest in a US-based therapeutics company and asked Alacrita to perform a technical DD. The target company was using a proprietary...
Learn More

Opportunity analysis of an antibody-cleaving enzyme in oncology & autoimmune diseases

Challenge: A biopharmaceutical company with a focus on immunomodulatory compounds was looking to expand the application of its lead product in oncology, specifically, by adapting the product to...
Learn More

Indication selection assessment for clinical stage oncology small molecule

Challenge: A venture capital firm was interested in an independent indication selection strategic assessment of a clinical stage small molecule oncology asset they had invested in, based on the...
Learn More

Opportunity mapping in myelofibrosis for phase II product

Challenge: An inflammation and oncology-focused biotech company was looking to expand the clinical footprint of one of its phase II products. Our client was discussing the potential positioning of...
Learn More